Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

If Amgen can secure full approval for Lumakras ahead of the FDA's 14 December decision date for Mirati's drug, it could close off that route to market and force the company to wait for its own ...

Amgen's first-to-market KRAS inhibitor Lumakras has so far failed to live up to once-lofty sales expectations, but a new FDA approval could lend momentum to its growth. The US regulator has ...

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined ...

(RTTNews) - Amgen Inc. (AMGN), Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination therapy for the treatment of patients with KRAS G12C ...